Cargando…
Peginterferon Lambda-1a, a New Therapeutic for Hepatitis C Infection, from Bench to Clinic
Chronic infection with hepatitis C virus (HCV) is estimated to affect approximately 3% of the world's population and cause 350,000 deaths each year. For a number of years, the standard of care has been combination therapy with recombinant alfa interferons—originally as native proteins but more...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
XIA & HE Publishing Ltd
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521278/ https://www.ncbi.nlm.nih.gov/pubmed/26357610 http://dx.doi.org/10.14218/JCTH.2013.00014 |